Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion

被引:0
作者
W. Lloyd Clark
Mimi Liu
John Kitchens
Pin-wen Wang
Zdenka Haskova
机构
[1] Palmetto Retina Center,
[2] Colorado Retina Associates,undefined
[3] Retina Associates of Kentucky,undefined
[4] Genentech,undefined
[5] Inc.,undefined
来源
BMC Ophthalmology | / 19卷
关键词
Retinal vein occlusion; RVO; Branch retinal vein occlusion; BRVO; Central retinal vein occlusion; CRVO; Anti-VEGF; Ranibizumab;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 48 条
[1]  
Deramo VA(2003)Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire Arch Ophthalmol 121 1297-1302
[2]  
Cox TA(2011)The burden of disease of retinal vein occlusion: review of the literature Eye (Lond) 25 981-988
[3]  
Syed AB(2016)Retinal vein occlusions, from basics to the latest treatment Retina 36 432-448
[4]  
Lee PP(2011)Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study Ophthalmology 118 1594-1602
[5]  
Fekrat S(2011)Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study Ophthalmology 118 2041-2049
[6]  
Laouri M(2014)Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study Ophthalmology 121 2432-2442
[7]  
Chen E(2012)Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion Eur J Ophthalmol 22 1013-1018
[8]  
Looman M(2014)Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials Ophthalmology 121 1059-1066
[9]  
Gallagher M(2009)Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials Invest Ophthalmol Vis Sci 50 3629-3635
[10]  
Ho M(2010)Legal vision requirements for drivers in the United States Virtual Mentor 12 938-940